title: Phenotypic analysis of monocyte-derived dendritic cells loaded with tumor antigen with heat-shock cognate protein-70.
abstract: OBJECTIVE
  The cross-presentation system of tumor antigen by monocyte-derived dendritic cells (mo-DCs) has been observed under appropriate conditions. Both CD14-negative and CD1a-positive phenotypes were critical in our previous study. This study compared the phenotype of mo-DCs and identified the conditions that favored T helper-1 (Th1) cytokine production after stimulation with the hsc70 and NY-ESO-1 p157-165 epitope fusion protein (hsc70/ESO p157-165).
  
  
  METHODS
  The mo-DCs were induced from healthy donors. Their surface markers and cytokine production were examined after stimulation with hsc70/ESO p157-165.
  
  
  RESULTS
  CD1a(+) and CD1a(-) mo-DCs were generated in half of the healthy donors. The concentration of fetal calf serum in the culture medium was critical for the induction of CD1a(+) DCs, which were able to produce interleukin-12 (IL-12), but not IL-10. Neutralizing IL-6 and IL-6R antibodies affected the expression of CD1a.
  
  
  CONCLUSIONS
  Anti IL-6 analogs may be effective adjuvants for the development of mo-DC-based cancer vaccine.
authors.affiliation: Department of Surgery, Division of Immunology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. ito0701@siren.ocn.ne.jp
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ito
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nagata
authors.forename: Seiya
authors.initials: S
authors.lastname: Susumu
authors.forename: Akira
authors.initials: A
authors.lastname: Yoneda
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Matsuo
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Yui
authors.forename: Heiichiro
authors.initials: H
authors.lastname: Udono
authors.forename: Susumu
authors.initials: S
authors.lastname: Eguchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Kanematsu
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D045142:Cross-Priming / Q000276:immunology*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D005434:Flow Cytometry; D050883:HSC70 Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology; D010641:Phenotype
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D050883:HSC70 Heat-Shock Proteins; D015850:Interleukin-6; D009363:Neoplasm Proteins; D010446:Peptide Fragments; C504237:peptide NY-ESO-1 157-165